Newbridge Financial Services Group, Inc. Bristol Myers Squibb CO Transaction History

Newbridge Financial Services Group, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Sep 11, 2024	SELL	$40.25 - $52.99 $1,408 - $1,854	-35 Reduced 1.83%	1,875 $77,000
Q1 2024 Apr 24, 2024	BUY	$47.98 - $54.4 $10,363 - $11,750	216 Added 12.75%	1,910 $103,000
Q4 2023 Mar 28, 2024	SELL	$48.48 - $57.85 $45,425 - $54,205	-937 Reduced 35.61%	1,694 $86,000
Q3 2023 Oct 17, 2023	SELL	$57.89 - $64.73 $1,563 - $1,747	-27 Reduced 1.02%	2,631 $152,000
Q2 2023 Jul 21, 2023	SELL	$63.71 - $70.74 $8,027 - $8,913	-126 Reduced 4.53%	2,658 $169,000
Q1 2023 Apr 18, 2023	SELL	$65.71 - $74.53 $4,796 - $5,440	-73 Reduced 2.56%	2,784 $192,000
Q4 2022 Jan 17, 2023	BUY	$68.48 - $81.09 $81,833 - $96,902	1,195 Added 71.9%	2,857 $0
Q3 2022 Oct 13, 2022	BUY	$0.13 - $76.84 $3 - $2,228	29 Added 1.78%	1,662 $118,000
Q2 2022 Jul 15, 2022	SELL	$72.62 - $79.98 $7,697 - $8,477	-106 Reduced 6.1%	1,633 $126,000
Q1 2022 Apr 26, 2022	BUY	$61.48 - $73.72 $4,795 - $5,750	78 Added 4.7%	1,739 $127,000
Q4 2021 Jan 19, 2022	SELL	$53.63 - $62.52 $1,179 - $1,375	-22 Reduced 1.31%	1,661 $104,000
Q3 2021 Oct 27, 2021	SELL	$59.17 - $69.31 $23,372 - $27,377	-395 Reduced 19.01%	1,683 $100,000
Q2 2021 Sep 07, 2021	SELL	$61.91 - $67.42 $9,162 - $9,978	-148 Reduced 6.65%	2,078 $139,000
Q1 2021 Sep 07, 2021	SELL	$59.34 - $66.74 $13,588 - $15,283	-229 Reduced 9.33%	2,226 $141,000
Q4 2020 Sep 07, 2021	SELL	$57.74 - $65.43 $11,201 - $12,693	-194 Reduced 7.32%	2,455 $152,000
Q3 2020 Sep 07, 2021	BUY	$57.43 - $63.64 $152,132 - $168,582	2,649 New	2,649 $160,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.